Brind.

The FDA is reviewing the label expansion application for Pyrukynd, a drug involving Agios Pharmaceuticals and Phathom Pharmaceuticals, Inc.

1 report, 1 independent Updated Jul 10

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Agios Pharmaceuticals

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Agios Pharmaceuticals
a public American pharmaceutical company
- Trump's pledge to unleash oil and gas benefits certain stocks.Sun 02:30

Coverage

Newest first; wire copies grouped

Jul 10ZacksAgios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? Agios Pharmaceuticals AGIO shares ended the last trading session 7.7% higher at $39.07. The jump came on an impressive volume